Project: Group III metabotropic glutamate receptors (mGluRs): from new molecules to therapeutic development for the treatment of Parkinson’s disease

Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the loss of dopaminergic (DA) neurons of the substantia nigra pars compacta in Parkinson’s disease (PD), represents a major challenge to treat Parkinsonian patients and avoid long-term L-DOPA-induced dyskinesia. Recent studies have focused on the modulatory action of metabotropic glutamate receptors (mGluRs) on neurodegenerative diseases including PD and subtypes 4 and 7 mGluRs (belonging to group III) are largely expressed in the basal ganglia. The objectives of the project are to gather the expertise of five different international teams and use their individual skills in chemistry, pharmacology, behavior, quantitative morphology and molecular biology to achieve a complete picture of "candidate" molecules for PD treatment that have agonist action at mGluR4 and 7, from their chemical structure-based design to their physiological action. Analyzing the functional and cellular impact of treatments activating these receptors will be essential to identify the best pharmacological anti-glutamate neuroprotective and neurorestorative strategy alternative to surgery in PD treatment.

Acronym	mGluRpatho
Duration	27/01/2009 - 26/01/2012
Network	NEURON
Call	NEURON-2008 Neurodegeneration

Project partner

Number	Name	Role	Country
1	CNRS_ Aix-Marseille Universite	Coordinator	France
2	CNRS_ Universite Descartes Paris V	Partner	France
3	I.R.C.C.S.	Partner	Italy
4	Karolinska Institutet	Partner	Sweden